Адаптация русскоязычной версии индекса активности системной красной волчанки EASY-BILAG

   Оценка активности системной красной волчанки (СКВ) имеет важное значение для определения эффективности лечения и принятия решения о дальнейшей терапии. Русскоязычные версии индексов активности необходимы для удовлетворения потребностей русскоязычной популяции пациентов и клиницистов и облегчения использования этих инструментов в клинической практике. Одним из важных шагов в этом направлении является адаптация индекса Easy-BILAG, которая служит более точной оценке активности заболевания и адекватному подбору терапии у пациентов с СКВ.

1. Решетняк ТМ. Системная красная волчанка. В кн.: Бадокин ВВ, редактор. Ревматология. Клинические лекции. Москва: Литтера; 2012. С. 245-331.

2. Kiriakidou M, Ching CL. Systemic Lupus Erythematosus. Ann Intern Med. 2020 Jun 2;172(11):ITC81-ITC96. doi: 10.7326/AITC202006020.

3. Lee YH, Choi SJ, Ji JD, Song GG. Overall and cause-specific mortality in systemic lupus erythematosus: an updated meta-analysis. Lupus. 2016 Jun;25(7):727-34. doi: 10.1177/0961203315627202.

4. Tselios K, Gladman DD, Touma Z, et al. Disease course patterns in systemic lupus erythematosus. Lupus. 2019 Jan;28(1):114-122. doi: 10.1177/0961203318817132.

5. Thanou A, Jupe E, Purushothaman M, et al. Clinical disease activity and flare in SLE: Current concepts and novel biomarkers. J Autoimmun. 2021 May;119:102615. doi: 10.1016/j.jaut.2021.102615.

6. Stoll T, Sutcliffe N, Mach J, et al. Analysis of the relationship between disease activity and damage in patients with systemic lupus erythematosus – a 5-yr prospective study. Rheumatology (Oxford). 2004 Aug;43(8):1039-44. doi: 10.1093/rheumatology/keh238.

7. Gensous N, Marti A, Barnetche T, et al. Predictive biological markers of systemic lupus erythematosus flares: a systematic literature review. Arthritis Res Ther. 2017 Oct 24;19(1):238. doi: 10.1186/s13075-017-1442-6.

8. Van Vollenhoven RF, Mosca M, Bertsias G, et al. Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis. 2014 Jun;73(6):958-67. doi: 10.1136/annrheumdis-2013-205139.

9. Feld J, Isenberg D. Why and how should we measure disease activity and damage in lupus? Presse Med. 2014 Jun;43(6 Pt 2):e151-6. doi: 10.1016/j.lpm.2014.03.002.

10. Ceccarelli F, Perricone C, Massaro L, et al. Assessment of disease activity in Systemic Lupus Erythematosus: Lights and shadows. Autoimmun Rev. 2015 Jul;14(7):601-8. doi: 10.1016/j.autrev.2015.02.008.

11. Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002 Feb;29(2):288-91.

12. Bombardier C, Gladman DD, Urowitz MB, et al. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 1992 Jun;35(6):630-40. doi: 10.1002/art.1780350606.

13. Banjari M, Touma Z, Gladman DD. Improving measures of disease activity in systemic lupus erythematosus. Expert Rev Clin Immunol. 2023 Feb;19(2):193-202. doi: 10.1080/1744666X.2023.2156339.

14. Jesus D, Matos A, Henriques C, et al. Derivation and validation of the SLE Disease Activity Score (SLE-DAS): a new SLE continuous measure with high sensitivity for changes in disease activity. Ann Rheum Dis. 2019 Mar;78(3):365-371. doi: 10.1136/annrheumdis-2018-214502.

15. Isenberg DA, Rahman A, Allen E, et al. BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus. Rheumatology (Oxford). 2005 Jul;44(7):902-6. doi: 10.1093/rheumatology/keh624.

16. Brunner HI, Feldman BM, Bombardier C, et al. Sensitivity of the Systemic Lupus Erythematosus Disease Activity Index, British Isles Lupus Assessment Group Index, and Systemic Lupus Activity Measure in the evaluation of clinical change in childhood-onset systemic lupus erythematosus. Arthritis Rheum. 1999 Jul;42(7):1354-60. doi: 10.1002/1529-0131(199907)42:7<1354::AID-ANR8>3.0.CO;2-4.

17. Wells GA, Tugwell P, Kraag GR, et al. Minimum important difference between patients with rheumatoid arthritis: the patient's perspective. J Rheumatol. 1993 Mar;20(3):557-60.

18. Furie RA, Petri MA, Wallace DJ, et.al. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum. 2009 Sep 15;61(9):1143-51. doi: 10.1002/art.24698.

19. Luijten KM, Tekstra J, Bijlsma JW, Bijl M. The Systemic Lupus Erythematosus Responder Index (SRI); a new SLE disease activity assessment. Autoimmun Rev. 2012 Mar;11(5):326-9. doi: 10.1016/j.autrev.2011.06.011.

20. Wallace DJ, Kalunian K, Petri MA, et al. Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study. Ann Rheum Dis. 2014 Jan;73(1):183-90. doi: 10.1136/annrheumdis-2012-202760. Epub 2013 Jan 12.

21. Carter LM, Gordon C, Yee CS, et al. Easy-BILAG: a new tool for simplified recording of SLE disease activity using BILAG-2004 index. Rheumatology (Oxford). 2022 Oct 6;61(10):4006-4015. doi: 10.1093/rheumatology/keab883.